Xi'er'an Pharmaceutical

Chongqing Xi'er'an Pharmaceutical Co., Ltd. originated from the 'Wu Shufang Aroma Room' in the 37th year of Emperor Kangxi (AD 1698). 'Wu Shufang' is a recognized China Time-honored Brand and a Chongqing Intangible Cultural Heritage.

Xi'er'an Pharmaceutical has always adhered to the corporate philosophy of 'Virtue over the world, medicine benefits all'. It has now developed into a comprehensive pharmaceutical enterprise integrating R&D, production, and sales, with total assets of 3 billion yuan. The enterprise has been successively rated as a National High-tech Enterprise, a National Intellectual Property Demonstration Enterprise, a Leading Enterprise of the National Bio-industry Base, a National Key Leading Enterprise in Agricultural Industrialization, as well as a 'National-level Green Factory' certified by the Ministry of Industry and Information Technology.

The production base of Xi'er'an is located in the Hechuan District Industrial Park of Chongqing, covering an area of 400 mu. It has 18 production lines for traditional Chinese medicines (TCM) of different dosage forms, all of which have passed the new national GMP compliance checks, with an annual output of 5,000 tons of proprietary Chinese medicines. The enterprise vigorously promotes the construction of intelligent manufacturing, with a total investment of 1.2 billion yuan. It has built a digital production plant for proprietary Chinese medicines, establishing a data-driven intelligent manufacturing system, achieving intelligent production processes, lean operation management, and scientific environmental protection. It has been awarded the 'National-level Green Factory' and 'Chongqing Digital Workshop'.

The enterprise is committed to building a community of shared interests between manufacturers and distributors, implementing an omnichannel marketing strategy, and achieving systematic development. The sales network covers all provinces, autonomous regions, and municipalities in China except Hong Kong, Macao, Taiwan, and Tibet. It has formed a sales pattern with deep cultivation from general hospitals in provincial capitals to district and county hospitals, township health centers, individual clinics, and retail pharmacies. It has established product lines with market competitive advantages in fields such as rheumatology, orthopedics, dermatology, respiratory medicine, cardiovascular and cerebrovascular medicine, pediatrics, gynecology, and sleep products.

As of the end of 2024, the enterprise has 101 varieties listed in the 'National Basic Medical Insurance Drug Catalog', 31 varieties in the 'National Essential Drug List', and 29 exclusive varieties. Some key products such as Shexiang Zhuifeng Zhitong Ointment, Dieda Qili Tablets, and Jinchan Zhiyang Capsules are exclusive or patented products, which have won national or provincial science and technology progress awards, Chongqing Major New Products, Chongqing High-tech Products, and other honors. Currently, two varieties, Shexiang ZhuiFeng ZhiTong Ointment and Dieda Qili Tablets, are national TCM protection varieties (valid until January 19, 2030); a total of 15 varieties have obtained national TCM variety protection.

Xi'er'an adheres to the scientific research strategy of 'Technology serves humanity, innovation promotes development', follows the R&D policy of 'combining imitation and innovation, and valuing both drugs and health products', and forms an R&D pattern of 'screening a batch, developing a batch, and reserving a batch'. The enterprise's R&D institution, Chongqing Sike Pharmaceutical Research Institute Co., Ltd., is a National Enterprise Technology Center, a Chongqing Postdoctoral Research Workstation, a Chongqing TCM Preparation Process Engineering Technology Research Center, and a Chongqing Industrial and Information Technology Key Laboratory of TCM Rubber Plasters.

The enterprise actively explores mechanisms of joint education, school-enterprise co-construction, and industry-education integration. It jointly builds a 'Biopharmaceutical Collaborative Innovation Center' to promote scientific and technological exchanges and cooperation among universities, research institutes, and enterprises, and to facilitate the transformation of innovative achievements. Cooperative partners include: China Academy of Chinese Medical Sciences, Academy of Military Medical Sciences, Beijing University of Chinese Medicine, Georgia Institute of Technology, West China Medical University, Army Medical University, Chengdu University of TCM, Chongqing Medical University, Chongqing Academy of Chinese Materia Medica, etc.

Up to now, the enterprise has a total of 213 drug production approvals; it has accumulated 200 Chinese patent applications, with 50 valid invention patents and 7 new drug certificates; it has formulated or revised 100 national standards; it has won 4 Chongqing Science and Technology Progress Awards; it has undertaken more than 40 national-level and municipal-level scientific research projects; it has received funding from 3 National Innovation Fund for Small and Medium-sized Technology-based Enterprises; it has participated in 3 National Major New Drug Innovation Projects; multiple products have been rated as China Famous Brand Products, National Key New Products, Chongqing Famous Products, Chongqing Excellent New Products, Chongqing Key New Products, Chongqing Major New Products, and Chongqing High-tech Products.

The enterprise vigorously implements the '10050 Strategy', insists on taking TCM modernization as the core strategic path, vertically integrates the industry chain, horizontally expands business segments, and builds a comprehensive health ecosystem. It focuses on the three strategic resources of talent, technology, and products, and strives to build organizational capabilities that support rapid growth. It inherits the brand essence of 'Wu Shufang', promotes TCM culture, adheres to bottom lines, and operates in compliance.